JP2017522277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522277A5 JP2017522277A5 JP2016570862A JP2016570862A JP2017522277A5 JP 2017522277 A5 JP2017522277 A5 JP 2017522277A5 JP 2016570862 A JP2016570862 A JP 2016570862A JP 2016570862 A JP2016570862 A JP 2016570862A JP 2017522277 A5 JP2017522277 A5 JP 2017522277A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462009910P | 2014-06-10 | 2014-06-10 | |
| US62/009,910 | 2014-06-10 | ||
| PCT/US2015/034964 WO2015191630A1 (en) | 2014-06-10 | 2015-06-09 | Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522277A JP2017522277A (ja) | 2017-08-10 |
| JP2017522277A5 true JP2017522277A5 (enExample) | 2018-07-19 |
| JP6552061B2 JP6552061B2 (ja) | 2019-07-31 |
Family
ID=54834213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570862A Active JP6552061B2 (ja) | 2014-06-10 | 2015-06-09 | 代謝型グルタミン酸受容体の負のアロステリックモジュレーター（ｎａｍｓ）とその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US9969726B2 (enExample) |
| EP (1) | EP3154954B1 (enExample) |
| JP (1) | JP6552061B2 (enExample) |
| AU (1) | AU2015274781C1 (enExample) |
| CA (1) | CA2950952C (enExample) |
| WO (1) | WO2015191630A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015157187A1 (en) * | 2014-04-06 | 2015-10-15 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof |
| WO2015191630A1 (en) | 2014-06-10 | 2015-12-17 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof |
| RS59220B1 (sr) | 2015-06-03 | 2019-10-31 | Bristol Myers Squibb Co | 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primenu u lečenju kardiovaskularnih poremećaja |
| CN108299303B (zh) * | 2018-02-09 | 2022-10-11 | 中山大学 | 一种四芳基吡唑类化合物的合成新方法 |
| CN108997325B (zh) * | 2018-07-06 | 2020-08-04 | 浙江工业大学 | 一种芳基联噻唑类化合物和应用 |
| CA3145507A1 (en) * | 2018-07-27 | 2020-01-30 | Daniel Pierce RADIN | Clinical methods and pharmaceutical compositions employing ampa receptor antagonists to treat glioblastoma and other cancers |
| US12366579B2 (en) * | 2019-03-21 | 2025-07-22 | University Of Virginia Patent Foundation | Sulfur-heterocycle exchange chemistry and uses thereof |
| CN110183382A (zh) * | 2019-06-06 | 2019-08-30 | 东北师范大学 | 新型三氟甲基吡唑类化合物合成方法 |
| AU2020316364A1 (en) * | 2019-07-22 | 2022-02-24 | Angion Biomedica Corp. | Ethynylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors |
| EP4074700A4 (en) | 2019-12-10 | 2024-02-07 | Shionogi & Co., Ltd | HISTONE DEACETYLASE INHIBITOR COMPRISING AROMATIC HETEROCYCLIC GROUP CONTAINING NITROGEN |
| CA3194203A1 (en) * | 2020-09-14 | 2022-03-17 | Genzyme Corporation | Carboxylic acid-containing compounds as modulators of bis-phosphoglycerate mutase for the treatment of sickle cell disease |
| CN112480073B (zh) * | 2020-12-02 | 2022-03-22 | 武汉药明康德新药开发有限公司 | 1-烷基-3,5-芳基取代的1,2,4三氮唑化合物的合成方法 |
| US20220265601A1 (en) * | 2021-02-10 | 2022-08-25 | David Alan Heldreth, JR. | Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses. |
| CN116041277B (zh) * | 2023-01-18 | 2024-11-01 | 中国药科大学 | 苯基和联苯基取代的五元杂环类化合物及其制备方法、药物组合物和应用 |
| US11970460B1 (en) | 2023-10-24 | 2024-04-30 | King Faisal University | 4-(4,5-bis(4-bromophenyl)-2-phenyl-1H-imidazol-1-yl)benzoic acid as an antimicrobial compound |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE250039T1 (de) | 1999-10-15 | 2003-10-15 | Hoffmann La Roche | Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten |
| ATE261945T1 (de) | 1999-10-15 | 2004-04-15 | Hoffmann La Roche | Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten |
| KR100838447B1 (ko) * | 2001-02-21 | 2008-06-16 | 아스트라제네카 아베 | 헤테로폴리시클릭 화합물 및 대사향성 글루타메이트수용체 길항제로서의 그의 용도 |
| CA2442557C (en) * | 2001-04-12 | 2008-12-23 | F. Hoffmann-La Roche Ag | Dihydro-benzo¬b|¬1,4|diazepin-2-one derivatives as mglur2 antagonists ii |
| NZ528345A (en) | 2001-04-12 | 2005-04-29 | F | Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mGluR2 antagonists I |
| JP4523271B2 (ja) * | 2001-06-01 | 2010-08-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチアゾール化合物 |
| US6949542B2 (en) * | 2002-02-06 | 2005-09-27 | Hoffman-La Roche Inc. | Dihydro-benzo[b][1,4]diazepin-2-one derivatives |
| WO2003077918A1 (en) * | 2002-03-12 | 2003-09-25 | Merck & Co., Inc. | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| WO2004058176A2 (en) * | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Acyclic pyrazole compounds |
| CN100422175C (zh) * | 2003-04-03 | 2008-10-01 | 麦克公司 | 作为代谢型谷氨酸受体-5调制剂的四环咪唑衍生物 |
| US20090018150A1 (en) * | 2003-07-24 | 2009-01-15 | Asterand Uk Limited | 5-Ht2b Receptor Antagonists |
| WO2005110410A2 (en) * | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
| JP5237799B2 (ja) * | 2005-06-27 | 2013-07-17 | エグゼリクシス パテント カンパニー エルエルシー | ピラゾールベースのｌｘｒモジュレーター |
| CA2646732C (en) | 2006-03-29 | 2015-04-28 | F. Hoffmann-La Roche Ag | Pyridine and pyrimidine derivatives as mglur2 antagonists |
| US8012986B2 (en) * | 2007-04-02 | 2011-09-06 | Hoffmann-La Roche Inc. | Pyridine and pyrimidine derivatives as MGLUR2 antagonists |
| EP2145873A1 (fr) | 2008-06-17 | 2010-01-20 | Commissariat A L'energie Atomique | Nouveaux composés ayant une activité protectrice vis-à-vis de l'action de toxines et de virus au mode d'action intracellulaire |
| WO2011073119A1 (en) | 2009-12-14 | 2011-06-23 | N.V. Organon | Mk2 inhibitors |
| US8748632B2 (en) * | 2010-03-19 | 2014-06-10 | Sanford-Burnham Medical Research Institute | Positive allosteric modulators of group II mGluRs |
| WO2013033246A2 (en) | 2011-08-29 | 2013-03-07 | Braincells, Inc. | Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof |
| GB201321743D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| WO2015191630A1 (en) | 2014-06-10 | 2015-12-17 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof |
-
2015
- 2015-06-09 WO PCT/US2015/034964 patent/WO2015191630A1/en not_active Ceased
- 2015-06-09 EP EP15806027.7A patent/EP3154954B1/en active Active
- 2015-06-09 US US15/315,363 patent/US9969726B2/en active Active
- 2015-06-09 CA CA2950952A patent/CA2950952C/en active Active
- 2015-06-09 AU AU2015274781A patent/AU2015274781C1/en active Active
- 2015-06-09 JP JP2016570862A patent/JP6552061B2/ja active Active
-
2018
- 2018-04-11 US US15/950,683 patent/US10597367B2/en active Active
-
2020
- 2020-03-12 US US16/817,209 patent/US11447453B2/en active Active
-
2022
- 2022-08-08 US US17/883,255 patent/US20230113588A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522277A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2013519675A5 (enExample) | ||
| JP2015516427A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2020532547A5 (enExample) | ||
| JP2012144574A5 (enExample) | ||
| JP2014508811A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2014508753A5 (enExample) | ||
| JP2015024998A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2018510138A5 (enExample) | ||
| JP2012092103A5 (enExample) | ||
| JP2014507455A5 (enExample) | ||
| JP2019531279A5 (enExample) | ||
| RU2016105436A (ru) | Нейроактивные стероиды, композиции и их использование | |
| JP2015508092A5 (enExample) | ||
| JP2019520344A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| EA201070783A1 (ru) | 1,2,4-оксадизольные соединения для лечения аутоиммунных заболеваний | |
| JP2016503797A5 (enExample) | ||
| JP2016510326A5 (enExample) |